WESTBOROUGH, Mass., March 23 /PRNewswire/ -- IBC’s 3rd Annual Molecular Diagnostics and 6th Annual Personalized Medicine events, scheduled for June 2- 4, 2004 at the Hyatt Regency Princeton in Princeton, NJ, are in their second year of being teamed up, creating an even bigger, better, and more synergistic event than ever. The objective of this combined event is to bring together the community of diagnostics, pharmaceutical, academia and biotechnology companies striving towards the goal of pharmacogenomics and individualized medicine.
“A key objective of life sciences research today is to identify the molecular events that are responsible for human disease on-set and progression. The successful translation of these insights into clinically robust assays will provide better diagnostic and predictive tests for both disease detection and treatment selection,” says Douglas P. Malinowski, Ph.D., Vice President and Chief Scientific Officer of TriPath Imaging and member of the Advisory Board for the two events. This combined program will do just that by offering technology updates, FDA perspectives, industry insights, and US and international outlook from the leading minds of the industry.
The first day of the combined event focuses on technologies and advancements in understanding the molecular basis of infectious diseases, oncology, and neurodegeneration disorders as well as biomarker discovery and molecular technologies in clinical utility. To provide a comprehensive overview and opportunity for discussion, the conference will feature an interactive panel discussion on adoption & reimbursement challenges, a talk on shareholders’ expectations and a discussion on licensing, technology transfer and joint ventures.
The second day will bring attendees from both events together to deliberate regulatory issues, forecast industry outlook and converge on the understanding of the molecular mechanisms of genes to diseases.
The final day digs into insights on drug responses and therapeutic outcomes of the various disease areas, such as oncology, infectious diseases, cardiovascular and psychiatry. US & International advancements in clinical pharmacogenomics will also be highlighted. “This meeting provided intense, focused discussion on the key issue to solve the bottlenecks of the pharmaceutical industry,” noted last year’s attendee, Dr. Kalev Kask, CEO of Egeen International.
ATTENTION CALENDAR EDITORS! For more information on attending IBC’s Molecular Diagnostics and Personalized Medicine on June 2-4, 2004 at the Hyatt Regency Princeton, in Princeton, NJ visit http://www.lifesciencesinfo.com/3001; call 508-616-5550 or e-mail kpatterson@ibcusa.com.
CONTACT: Kerry Patterson
EMAIL: kpatterson@ibcusa.com
IBC
CONTACT: Kerry Patterson of IBC, kpatterson@ibcusa.com
Web site: http://www.lifesciencesinfo.com/
